secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2022-05-03T23:59:59+00:00
Accession:  0001808805-22-000044
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Biotechnology Q1 net loss widens to $15.8M on higher R&D and G&A costs
-------------------------------------------------------------------------------

- Operating expenses $16.0M, up 90% YoY from $8.4M, driven by headcount and public company costs.
- Net loss $15.8M vs $8.4M in prior year; no revenue reported (pre-revenue proteomics platform).
- Cash, cash equivalents, and investments $349.0M as of March 31, 2022.
- Scientific progress: manuscript on single-molecule protein arrays, Genentech collaboration results, and AACR antibody data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880522000044/0001808805-22-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880522000044/naut-20220503.htm
  HTML page:      https://secwatch.observer/filing/0001808805-22-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer